(Q36221544)

12 August 2017

1 reference

title

CD 33 as a target of therapy in acute myeloid leukemia: current status and future perspectives (English)

1 reference

12 August 2017

main subject

acute myeloid leukemia

1 reference

1

Wolfgang R Sperr

1 reference

12 August 2017

Stefan Florian

2

1 reference

12 August 2017

Alexander W Hauswirth

series ordinal

3

1 reference

12 August 2017

Peter Valent

series ordinal

4

1 reference

12 August 2017

publication date

1 August 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

46

1 reference

12 August 2017

issue

8

1 reference

12 August 2017

page(s)

1115-1120

1 reference

Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190500126075

Multidrug resistance in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500126075

Therapeutic options for acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500126075

Prognostic factors in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500126075

New developments in antibody therapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500126075

Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500126075

Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500126075

Human leukaemic stem cells: a novel target of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500126075

Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500126075

Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500126075

Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500126075

Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500126075

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500126075

Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500126075

10.1080/10428190500126075

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference